FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007285147> ?p ?o ?g. }

• W2007285147 endingPage "936" @default.
• W2007285147 startingPage "928" @default.
• W2007285147 abstract "Summary Purpose We aimed to investigate the recommended dose for the combination of TSU-68, a multiple-receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2 and platelet-derived growth factor receptor-β, and S-1, an oral fluoropyrimidine, in patients with advanced hepatocellular carcinoma (HCC) based on its associated dose-limiting toxicity (DLT) frequency. We also determined the safety, tolerability, pharmacokinetics (PK), and efficacy of the combination treatment. Patients and methods Patients without any prior systemic therapy received 400 mg/day TSU-68 orally and 80 mg/day (level 1) or 100 mg/day (level 2) S-1 for 4 or 2 weeks followed by a 2- or 1-week rest period (groups A and B, respectively). According to the treatment, patients progressed from level 1B to level 2A, then level 2B. Safety and response rates were assessed. Results Eighteen patients were enrolled. Two patients at levels 1B and 2A but none at level 2B showed DLTs. The common adverse drug reactions were a decrease in hemoglobin levels, hypoalbuminemia, and anorexia, which were mild in severity (grades 1–2). PK data from levels 1B and 2A indicated that the area under the curve for TSU-68 and 5-fluorouracil was unlikely to be affected by the combination treatment. Response rate, disease control rate, median time to progression, and median overall survival were 27.8 %, 61.1 %, 5.3 months, and 12.8 months, respectively. Conclusion The recommended dose for advanced HCC should be 400 mg/day TSU-68 and 100 mg/day S-1 for 4 weeks followed by 2-week rest." @default.
• W2007285147 created "2016-06-24" @default.
• W2007285147 creator A5005262911 @default.
• W2007285147 creator A5009985299 @default.
• W2007285147 creator A5021407007 @default.
• W2007285147 creator A5022537134 @default.
• W2007285147 creator A5024011175 @default.
• W2007285147 creator A5025188852 @default.
• W2007285147 creator A5030360078 @default.
• W2007285147 creator A5033386967 @default.
• W2007285147 creator A5040581923 @default.
• W2007285147 creator A5046522736 @default.
• W2007285147 creator A5054771200 @default.
• W2007285147 creator A5059201555 @default.
• W2007285147 creator A5074627346 @default.
• W2007285147 creator A5076696174 @default.
• W2007285147 creator A5080299485 @default.
• W2007285147 date "2014-05-15" @default.
• W2007285147 modified "2023-09-30" @default.
• W2007285147 title "Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma" @default.
• W2007285147 cites W1512977690 @default.
• W2007285147 cites W1965309017 @default.
• W2007285147 cites W1965929829 @default.
• W2007285147 cites W1971837077 @default.
• W2007285147 cites W1981187143 @default.
• W2007285147 cites W1993322072 @default.
• W2007285147 cites W1994193851 @default.
• W2007285147 cites W1996229105 @default.
• W2007285147 cites W2001856011 @default.
• W2007285147 cites W2002741555 @default.
• W2007285147 cites W2004274458 @default.
• W2007285147 cites W2007196889 @default.
• W2007285147 cites W2010983989 @default.
• W2007285147 cites W2016364458 @default.
• W2007285147 cites W2020830322 @default.
• W2007285147 cites W2053526872 @default.
• W2007285147 cites W2056379954 @default.
• W2007285147 cites W2080663543 @default.
• W2007285147 cites W2096167489 @default.
• W2007285147 cites W2154566601 @default.
• W2007285147 cites W2160151760 @default.
• W2007285147 cites W2163473774 @default.
• W2007285147 cites W2163486683 @default.
• W2007285147 cites W2170783473 @default.
• W2007285147 doi "https://doi.org/10.1007/s10637-014-0109-2" @default.
• W2007285147 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4169869" @default.
• W2007285147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24829073" @default.
• W2007285147 hasPublicationYear "2014" @default.
• W2007285147 type Work @default.
• W2007285147 sameAs 2007285147 @default.
• W2007285147 citedByCount "5" @default.
• W2007285147 countsByYear W20072851472015 @default.
• W2007285147 countsByYear W20072851472016 @default.
• W2007285147 countsByYear W20072851472018 @default.
• W2007285147 countsByYear W20072851472021 @default.
• W2007285147 crossrefType "journal-article" @default.
• W2007285147 hasAuthorship W2007285147A5005262911 @default.
• W2007285147 hasAuthorship W2007285147A5009985299 @default.
• W2007285147 hasAuthorship W2007285147A5021407007 @default.
• W2007285147 hasAuthorship W2007285147A5022537134 @default.
• W2007285147 hasAuthorship W2007285147A5024011175 @default.
• W2007285147 hasAuthorship W2007285147A5025188852 @default.
• W2007285147 hasAuthorship W2007285147A5030360078 @default.
• W2007285147 hasAuthorship W2007285147A5033386967 @default.
• W2007285147 hasAuthorship W2007285147A5040581923 @default.
• W2007285147 hasAuthorship W2007285147A5046522736 @default.
• W2007285147 hasAuthorship W2007285147A5054771200 @default.
• W2007285147 hasAuthorship W2007285147A5059201555 @default.
• W2007285147 hasAuthorship W2007285147A5074627346 @default.
• W2007285147 hasAuthorship W2007285147A5076696174 @default.
• W2007285147 hasAuthorship W2007285147A5080299485 @default.
• W2007285147 hasBestOaLocation W20072851471 @default.
• W2007285147 hasConcept C112705442 @default.
• W2007285147 hasConcept C126322002 @default.
• W2007285147 hasConcept C141071460 @default.
• W2007285147 hasConcept C197934379 @default.
• W2007285147 hasConcept C2777288759 @default.
• W2007285147 hasConcept C2778019345 @default.
• W2007285147 hasConcept C2778375690 @default.
• W2007285147 hasConcept C29730261 @default.
• W2007285147 hasConcept C71924100 @default.
• W2007285147 hasConcept C90924648 @default.
• W2007285147 hasConcept C98274493 @default.
• W2007285147 hasConceptScore W2007285147C112705442 @default.
• W2007285147 hasConceptScore W2007285147C126322002 @default.
• W2007285147 hasConceptScore W2007285147C141071460 @default.
• W2007285147 hasConceptScore W2007285147C197934379 @default.
• W2007285147 hasConceptScore W2007285147C2777288759 @default.
• W2007285147 hasConceptScore W2007285147C2778019345 @default.
• W2007285147 hasConceptScore W2007285147C2778375690 @default.
• W2007285147 hasConceptScore W2007285147C29730261 @default.
• W2007285147 hasConceptScore W2007285147C71924100 @default.
• W2007285147 hasConceptScore W2007285147C90924648 @default.
• W2007285147 hasConceptScore W2007285147C98274493 @default.
• W2007285147 hasIssue "5" @default.
• W2007285147 hasLocation W20072851471 @default.
• W2007285147 hasLocation W20072851472 @default.
• W2007285147 hasLocation W20072851473 @default.

• next